Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)
 
 • Company Description   
Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

Number of Employees: 26

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.30 Daily Weekly Monthly
20 Day Moving Average: 132,748 shares
Shares Outstanding: 14.93 (millions)
Market Capitalization: $19.41 (millions)
Beta: 0.21
52 Week High: $6.40
52 Week Low: $1.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.24% 4.74%
12 Week -5.11% -16.85%
Year To Date -24.85% -29.03%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1951 NW 7TH AVENUE SUITE 520
-
MIAMI,FL 33136
USA
ph: 305-909-0840
fax: -
investorrelations@longeveron.com https://longeveron.com
 
 • General Corporate Information   
Officers
Mohamed Wa'el Ahmed Hashad - Chief Executive Officer
Lisa A. Locklear - Executive Vice President and Chief Financial Offic
Joshua M. Hare - Director
Rock Soffer - Director
Richard Kender - Director

Peer Information
Longeveron Inc. (CORR.)
Longeveron Inc. (RSPI)
Longeveron Inc. (CGXP)
Longeveron Inc. (BGEN)
Longeveron Inc. (GTBP)
Longeveron Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 54303L203
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 14.93
Most Recent Split Date: 3.00 (0.10:1)
Beta: 0.21
Market Capitalization: $19.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.13
Price/Cash Flow: -
Price / Sales: 8.72
EPS Growth
vs. Year Ago Period: 78.88%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -30.47%
vs. Previous Quarter: -36.82%
ROE
06/30/25 - -
03/31/25 - -85.07
12/31/24 - -97.60
ROA
06/30/25 - -
03/31/25 - -70.74
12/31/24 - -75.56
Current Ratio
06/30/25 - -
03/31/25 - 5.61
12/31/24 - 7.60
Quick Ratio
06/30/25 - -
03/31/25 - 5.61
12/31/24 - 7.60
Operating Margin
06/30/25 - -
03/31/25 - -760.72
12/31/24 - -667.77
Net Margin
06/30/25 - -
03/31/25 - -760.72
12/31/24 - -667.77
Pre-Tax Margin
06/30/25 - -
03/31/25 - -760.72
12/31/24 - -667.77
Book Value
06/30/25 - -
03/31/25 - 1.15
12/31/24 - 1.47
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.04
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 3.63
 

Powered by Zacks Investment Research ©